Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial

Identification of new medications for alcohol use disorder (AUD) is important for improving treatment options. Baclofen, a GABA(B) agonist, has been identified as a potential pharmacotherapy for AUD. In a 16-week double-blind, randomized, placebo-controlled trial, we investigated 30 and 90 mg/day of...

Descripción completa

Detalles Bibliográficos
Autores principales: Garbutt, James C., Kampov-Polevoy, Alexei B., Pedersen, Cort, Stansbury, Melissa, Jordan, Robyn, Willing, Laura, Gallop, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580979/
https://www.ncbi.nlm.nih.gov/pubmed/34155332
http://dx.doi.org/10.1038/s41386-021-01055-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580979/
https://www.ncbi.nlm.nih.gov/pubmed/34155332
http://dx.doi.org/10.1038/s41386-021-01055-w

Ejemplares similares